Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Biomaterials. 2021 Apr 27;274:120844. doi: 10.1016/j.biomaterials.2021.120844

Figure 3. NP Vacc elicits tumor-specific CD8+ T cell responses in the systemic compartment but fails to inhibit MC-38 tumor growth.

Figure 3.

a) Timeline of experiment. b) C57BL/6 mice were inoculated at s.c. flank with 6×105 MC-38 colon carcinoma cells on day 0 and vaccinated at s.c. tail base on day 7 with increasing doses of vaccines. Neoantigen-specific CD8+ T cell levels in blood circulation were quantified on day 14 by tetramer staining and flow cytometry. c) Shown are the average MC-38 tumor growth curves. d-e) Numbers of tumor-infiltrating d) CD3+CD8+ T cells and e) tetramer+CD3+CD8+ T cells were measured on day 14. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ****p < 0.0001, analyzed by one-way ANOVA, followed by Tukey’s HSD multiple comparison post hoc test.